Table 2.
Overview of studies investigating adrenomedullin in human patients with forms of heart failure
| Author (year) | Intervention | Condition | Effects |
|---|---|---|---|
| Nakamura67 (1997) | FBF and SBF test with intra‐arterial ADM |
Healthy subjects (n = 10) Patients with CHF (n = 18) |
↑ FBF & ↑ SBF Effects partially NO‐mediated Impaired FBF and SBF responses in CHF group |
| Nagaya68 (2000) | I.v. infusion of ADM (n = 7) or placebo (n = 6), 90 min total | Patients with precapillary pulmonary hypertension (n = 13 total) |
↑ Cardiac index (44%) ↓ Pulmonary arterial pressure (32%) ↓ MAP (9 mmHg), ↑ HR ↓ Plasma aldosterone (but not renin) No effect ANP/BNP |
| Nishikimi69 (2009) | I.v. infusion of ADM + hANP for 12 h, followed by 12 h of hANP | Acute heart failure patients with dyspnoea and pulmonary congestion (n = 7) |
ADM + hANP: ↓ MAP, PAP, systemic and pulmonary vascular resistance ↑ Cardiac output, urine volume and urinary sodium excretion ↓ Aldosterone, BNP, free‐radical metabolites |
| Kataoka70 (2010) |
I.v. infusion of ADM for 12 h No placebo arm |
Patients with acute myocardial infarction before undergoing PCI (n = 10) |
During infusion, two patients showed unstable haemodynamics MRI 3 vs. 1 month after PCI: ↑ Wall motion index, ↓ infarct size |
ADM, adrenomedullin; ANP, atrial natriuretic peptide; BNP, brain natriuretic peptide; CHF, chronic heart failure; FBF, forearm blood flow; hANP, human atrial natriuretic peptide; HR, heart rate; MAP, mean arterial pressure; MRI, magnetic resonance imaging; NO, nitric oxide; PAP, pulmonary artery pressure; PCI, percutaneous coronary intervention; SBF, skin blood flow.